Puma Biotechnology reports Q2 EPS 10c, consensus 1c

Reports Q2 revenue $54.6M, consensus $51.7M. “We are pleased to report both positive net income and positive cash flow for the second quarter of 2023,” said Alan H. Auerbach, CEO. “In addition, we announced positive biomarker data from the randomized trial of alisertib plus paclitaxel versus paclitaxel alone in hormone receptor positive, HER2-negative breast cancer at the recent 2023 Annual Meeting of the American Society of Clinical Oncology, which will be helpful as we move forward with the clinical development of alisertib in this indication.”